Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Vrdoljak E., Marschner N., Zielinski C., Gligorov J., Cortes J., Puglisi F., Aapro M., Fallowfield L., Fontana A., Inbar M., Kahán Zsuzsanna, Welt A., Lévy C., Brain E., Pivot X.: Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
ANNALS OF ONCOLOGY, 27 (11). pp. 2046-2052. ISSN 0923-7534 (2016)

[img]
Preview
Text
mdw316.pdf - Published Version

Download (261kB) | Preview
Item Type: Article
Journal or Publication Title: ANNALS OF ONCOLOGY
Date: 2016
Volume: 27
Number: 11
Page Range: pp. 2046-2052
ISSN: 0923-7534
Faculty: Faculty of Medicine
Institution: Szegedi Tudományegyetem
SWORD language: Angol
Identification Number: 3257982
DOI id: https://doi.org/10.1093/annonc/mdw316
Date Deposited: 2017. Aug. 30. 11:19
Last Modified: 2017. Aug. 30. 11:19
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/11866

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year